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Introduction
Carcinoma of the breast is the commonest malignancy in Hong Kong women, and in 2009 
it was ranked third as a cause of cancer mortality.1 The life-time risk for Hong Kong women 
is 1 in 19 and risk of consequential death 1 in 101. Evidently, 5% of the cases present as 
metastatic disease, common sites being lymph nodes, lung, liver, and bone.2 Metastases 
to other solid organs such as the urinary bladder are uncommon but have been reported 
sporadically. Patients with urinary bladder metastasis have very limited survival (about 1 
month to 2 years). We present the first reported case of carcinoma of breast with metastasis 
to urinary bladder in Hong Kong, with a structured review of this entity. 
Case report
An 83-year-old woman, with a history of left breast cancer and modified radical mastectomy 
performed more than 30 years earlier, presented in 2006 with a skin nodule on right chest 
wall. Biopsy of the right chest wall nodule showed metastatic adenocarcinoma which 
was oestrogen receptor (ER) positive, progesterone receptor (PR) positive, and c-ERBB2 
negative. Metastatic workup revealed diffuse metastases to right chest wall, left breast, 
left axillary lymph node, bone, adrenal gland, and peritoneal deposit. She received serial 
hormonal therapy including letrozole and exemestane together with radiotherapy to bony 
metastasis. Follow-up imaging with positron emission tomography–computed tomography 
(PET-CT) showed stabilisation of disease and fine-needle aspiration cytology of the left 
breast lesion only showed mild epithelial hyperplasia. Five years after the diagnosis of 
metastases, she presented with anaemic symptoms and volunteered a 2-week history of 
gross haematuria. The CT revealed a contrast-enhancing mass arising from left lateral wall 
of the urinary bladder. Flexible cystoscopy showed a 25 mm x 25 mm erythematous patch 
on the left lateral wall with an irregular surface (Fig), which was biopsied with haemostasis 
achieved by cautery. Histology revealed irregular, solid nests and trabeculae of round-
to-polygonal tumour cells. Rare glandular lumens lined by cells possessing a moderate 
amount of eosinophilic cytoplasm were also noted. On immunohistochemical staining, 
the tumour cells were positive for CK-7, and negative for CK-20 and GCDFP (gross cystic 
disease fluid protein). Moreover, ER and PR stains were avidly taken up while the C-ERBB2 
score was 2 (ie equivocal). Haemostasis was achieved with electrocautery and no further 
haematuria was observed. The latest PET-CT showed an interval increase in metabolic 
activity in most of the metastases, including that in the urinary bladder. The patient 
continues to receive chemotherapy and hormonal therapy and is currently alive more than 
6 years since the diagnosis of metastasis. 
Discussion
Urinary bladder secondaries are rare and account for 2% of all bladder neoplasms; most 
are discovered at autopsy.3,4 Known primaries include gastric cancer, melanoma, as well as 
breast and lung cancer. In a recent clinicopathological study of 11 patients with metastatic 
lesions in the urinary bladder, most were in women and frequently breast cancer (3/11).5 
Breast cancer commonly metastasises to lymph nodes, lung, liver and bone, whilst it rarely 
involves the brain, adrenals, spleen, thyroid, heart, or urinary bladder. In 1980, Haid et 
al6 reported a patient with urinary bladder metastases from breast carcinoma, although 
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Less than 5% of breast cancers present as metastasis, and urinary bladder secondaries were 
only sporadically reported in the literature. However, they may even be responsible for the 
initial presentation, for which reason they can pose a diagnostic challenge. We present here 
what we believe is the first such case in Hong Kong, with a review of this entity.
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有少於百分之五的乳癌會出現癌細胞轉移，至於癌細胞轉移至膀胱甚
為罕見。由於這些轉移的癌細胞可能引致病人出現首發的症狀，因
此引致診斷困難。本文報告一宗乳癌轉移到膀胱的病例，並對此等病
例進行回顧。我們相信這是香港有關癌細胞轉移至膀胱的首宗病例報
告。
乳癌細胞轉移膀胱的病例報告
autopsy reports date back to 1956.7 To date, there 
have been at least 40 reported cases of metastatic 
breast cancer to the bladder. 
 One postulated mechanism of secondary 
bladder tumours is from emboli that traverse 
the pulmonary circulation without causing lung 
metastasis, but do so upon reaching the urinary 
bladder haematogenously. Other possible 
mechanisms are through lymphatic or direct 
retroperitoneal invasion.8 
 The most common presenting symptom was 
urinary frequency and gross haematuria. Other 
presentations include difficulty in voiding, incidental 
finding on imaging, and/or ureteral obstruction or 
even urinary incontinence.5,9 Less-common findings 
include pelvic mass and bilateral hydronephrosis, 
and renal failure.10 Patients can present concomitantly 
with the primary tumour, or as a late metastasis, 
with time lapses exceeding 30 years.2 Our case 
demonstrates one of the longest time lapses between 
treatment of the primary tumour and presentation 
with a metastasis (more than 30 years). Rarely the 
diagnosis of breast cancer is made after bladder 
metastasis is discovered.2 As in our patient, most 
cases will have widespread metastases. However, 
a solitary metastasis to the urinary bladder has also 
been reported.11
 Diagnostic workup requires direct visualisation 
of the bladder mucosa by cystoscopy, and histological 
confirmation of a specimen obtained by means of 
cup biopsy or transurethral resection. Cystoscopic 
findings vary and include solid tumour, non-specific 
inflammatory patches, and thickened bladder wall 
with intact overlying mucosa (Fig). Upper urinary tract 
imaging is indicated when there is evidence of renal 
impairment suggesting obstructive nephropathy. 
Screening by means of magnetic resonance imaging 
or PET-CT may reveal other metastases. 
 Although ductal breast carcinoma is more 
common than the lobular subtype, infiltrating lobular 
carcinoma accounts for the majority of metastases to 
the bladder.2 The latter tends to occur as a diffuse 
thickening of mucosa rather than a discrete nodule.12 
To differentiate histological variants of primary 
bladder tumour from secondaries, absence of 
bladder mucosa alterations/lesions can be helpful. 
There may also be unusual monomorphic growth 
patterns without accompanying conventional 
urothelial carcinoma features, and the tumour can 
appear to invade towards the luminal surface from 
the outside.11 
 Additional means of avoiding diagnostic 
confusion is the utilisation of immunohistochemical 
staining for various markers. Common screening 
markers include cytokeratin, CK-7, CK-18, CK-19, 
CK-20, as well as ER/PR expression for tumours of 
suspected endometrial and breast origin. Other 
typical urothelial markers include p63, Ker903, 
thrombomodulin, GATA3, and CK5/6. Other markers 
to screen for cancers include prostate-specific antigen 
for prostate, thyroglobulin for thyroid, uroplakin 
III for urothelium, and HepPar I for hepatocellular 
origin.5
 Treatment of metastatic breast cancer involves 
a combination of chemotherapy and hormonal 
treatment, mainly anti-oestrogens. Local resection 
is mainly reserved for diagnostic purposes and 
amelioration of local symptoms. It is not curative, 
as the deposit is muscular rather than mucosal, and 
ER- and PR-positive tumours are more responsive to 
hormone therapy than their negative counterparts 
that have longer disease-free survivals.13 However, 
not uncommonly the ER/PR status of the metastatic 
lesion differs from that of the original tumour, and 
one study reported that the discordance rate was as 
high as 24%.14 Patients whose tumour status changed 
from positive to negative (positive/negative) have 
FIG.  Cystoscopic finding of a urinary bladder secondary
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shorter median survivals than positive/positive or 
negative/negative patients.15 In our case the original 
ER/PR status was unknown as the primary treatment 
was performed more than 30 years ago. Also, HER2-
positive breast cancer tends to be more aggressive 
and less responsive to hormone treatment than other 
breast cancers. In cases of obstructive uropathy, 
percutaneous drainage via ureteric catheterization 
should be performed to optimise renal function 
before initiation of chemotherapy. In terms of 
survival, there are reports of survival for more than 5 
years after diagnosis of bladder metastasis, but most 
patients die within 1 year.5 Our case is currently alive 
and receiving further hormonal manipulation. 
 The urinary bladder is an uncommon site of 
metastasis from breast cancer. Although routine 
screening of the lower urinary tract is not warranted 
for all patients, women with a history of breast 
cancer who present with urinary symptoms should 
be investigated to exclude such a bladder lesion. 
However, if the presence of a metastasis is confirmed, 
early initiation of appropriate treatment is warranted. 
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